Impact of statin use on heart failure mortality

Senthil K. Thambidorai, Anand R. Deshmukh, Ryan W. Walters, Paul D. Turner, Michael S. Monaghan, Aryan N. Mooss, Claire B. Hunter, Dennis J. Esterbrooks, Syed M. Mohiuddin

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: There is conflicting data regarding the mortality benefit of statins in patients with heart failure. The objectives of our study were to determine whether statin therapy is associated with decreased all-cause mortality and to assess the effect of incremental duration of therapy. Methods: We studied 10,510 consecutive patients from the Veterans Affairs health system with a diagnosis of heart failure from January 2002 through December 2006. Mean follow up was 2.66 years. Statin use and duration of therapy were identified. Veterans were classified into four groups based on duration of statin use during the study period (none, 1-25%, 26-75% and > 75% use of statins). Logistic regression was performed to identify the association between incident statin use and all-cause mortality following a diagnosis of heart failure. The Kaplan-Meier method was employed to assess for differences in survival time between the four statin use classifications. Results: Statin use was significantly associated with decreased all-cause mortality following a diagnosis of heart failure after controlling for age, gender, concurrent medications and comorbid diagnoses [χ 3 2 (N = 10,510) = 1077.82, p <0.001]. The benefit was seen within a relatively short duration (within 1 year) after starting statins, and in patients with <25% use of statins, there was no mortality benefit. Conclusion: Veterans who were not exposed to statin therapy at any time during the study period were 1.56 times more likely to suffer all-cause mortality.

Original languageEnglish
Pages (from-to)438-443
Number of pages6
JournalInternational Journal of Cardiology
Volume147
Issue number3
DOIs
StatePublished - Mar 17 2011

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Heart Failure
Mortality
Veterans
Veterans Health
Therapeutics
Logistic Models

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Impact of statin use on heart failure mortality. / Thambidorai, Senthil K.; Deshmukh, Anand R.; Walters, Ryan W.; Turner, Paul D.; Monaghan, Michael S.; Mooss, Aryan N.; Hunter, Claire B.; Esterbrooks, Dennis J.; Mohiuddin, Syed M.

In: International Journal of Cardiology, Vol. 147, No. 3, 17.03.2011, p. 438-443.

Research output: Contribution to journalArticle

Thambidorai, Senthil K. ; Deshmukh, Anand R. ; Walters, Ryan W. ; Turner, Paul D. ; Monaghan, Michael S. ; Mooss, Aryan N. ; Hunter, Claire B. ; Esterbrooks, Dennis J. ; Mohiuddin, Syed M. / Impact of statin use on heart failure mortality. In: International Journal of Cardiology. 2011 ; Vol. 147, No. 3. pp. 438-443.
@article{6f875e48eba5445f986a8662c8238868,
title = "Impact of statin use on heart failure mortality",
abstract = "Background: There is conflicting data regarding the mortality benefit of statins in patients with heart failure. The objectives of our study were to determine whether statin therapy is associated with decreased all-cause mortality and to assess the effect of incremental duration of therapy. Methods: We studied 10,510 consecutive patients from the Veterans Affairs health system with a diagnosis of heart failure from January 2002 through December 2006. Mean follow up was 2.66 years. Statin use and duration of therapy were identified. Veterans were classified into four groups based on duration of statin use during the study period (none, 1-25{\%}, 26-75{\%} and > 75{\%} use of statins). Logistic regression was performed to identify the association between incident statin use and all-cause mortality following a diagnosis of heart failure. The Kaplan-Meier method was employed to assess for differences in survival time between the four statin use classifications. Results: Statin use was significantly associated with decreased all-cause mortality following a diagnosis of heart failure after controlling for age, gender, concurrent medications and comorbid diagnoses [χ 3 2 (N = 10,510) = 1077.82, p <0.001]. The benefit was seen within a relatively short duration (within 1 year) after starting statins, and in patients with <25{\%} use of statins, there was no mortality benefit. Conclusion: Veterans who were not exposed to statin therapy at any time during the study period were 1.56 times more likely to suffer all-cause mortality.",
author = "Thambidorai, {Senthil K.} and Deshmukh, {Anand R.} and Walters, {Ryan W.} and Turner, {Paul D.} and Monaghan, {Michael S.} and Mooss, {Aryan N.} and Hunter, {Claire B.} and Esterbrooks, {Dennis J.} and Mohiuddin, {Syed M.}",
year = "2011",
month = "3",
day = "17",
doi = "10.1016/j.ijcard.2010.08.016",
language = "English",
volume = "147",
pages = "438--443",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Impact of statin use on heart failure mortality

AU - Thambidorai, Senthil K.

AU - Deshmukh, Anand R.

AU - Walters, Ryan W.

AU - Turner, Paul D.

AU - Monaghan, Michael S.

AU - Mooss, Aryan N.

AU - Hunter, Claire B.

AU - Esterbrooks, Dennis J.

AU - Mohiuddin, Syed M.

PY - 2011/3/17

Y1 - 2011/3/17

N2 - Background: There is conflicting data regarding the mortality benefit of statins in patients with heart failure. The objectives of our study were to determine whether statin therapy is associated with decreased all-cause mortality and to assess the effect of incremental duration of therapy. Methods: We studied 10,510 consecutive patients from the Veterans Affairs health system with a diagnosis of heart failure from January 2002 through December 2006. Mean follow up was 2.66 years. Statin use and duration of therapy were identified. Veterans were classified into four groups based on duration of statin use during the study period (none, 1-25%, 26-75% and > 75% use of statins). Logistic regression was performed to identify the association between incident statin use and all-cause mortality following a diagnosis of heart failure. The Kaplan-Meier method was employed to assess for differences in survival time between the four statin use classifications. Results: Statin use was significantly associated with decreased all-cause mortality following a diagnosis of heart failure after controlling for age, gender, concurrent medications and comorbid diagnoses [χ 3 2 (N = 10,510) = 1077.82, p <0.001]. The benefit was seen within a relatively short duration (within 1 year) after starting statins, and in patients with <25% use of statins, there was no mortality benefit. Conclusion: Veterans who were not exposed to statin therapy at any time during the study period were 1.56 times more likely to suffer all-cause mortality.

AB - Background: There is conflicting data regarding the mortality benefit of statins in patients with heart failure. The objectives of our study were to determine whether statin therapy is associated with decreased all-cause mortality and to assess the effect of incremental duration of therapy. Methods: We studied 10,510 consecutive patients from the Veterans Affairs health system with a diagnosis of heart failure from January 2002 through December 2006. Mean follow up was 2.66 years. Statin use and duration of therapy were identified. Veterans were classified into four groups based on duration of statin use during the study period (none, 1-25%, 26-75% and > 75% use of statins). Logistic regression was performed to identify the association between incident statin use and all-cause mortality following a diagnosis of heart failure. The Kaplan-Meier method was employed to assess for differences in survival time between the four statin use classifications. Results: Statin use was significantly associated with decreased all-cause mortality following a diagnosis of heart failure after controlling for age, gender, concurrent medications and comorbid diagnoses [χ 3 2 (N = 10,510) = 1077.82, p <0.001]. The benefit was seen within a relatively short duration (within 1 year) after starting statins, and in patients with <25% use of statins, there was no mortality benefit. Conclusion: Veterans who were not exposed to statin therapy at any time during the study period were 1.56 times more likely to suffer all-cause mortality.

UR - http://www.scopus.com/inward/record.url?scp=79952486657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952486657&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2010.08.016

DO - 10.1016/j.ijcard.2010.08.016

M3 - Article

VL - 147

SP - 438

EP - 443

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -